Candidemia in the pediatric patient with burns

The Journal of Burn Care & Rehabilitation
R L SheridanR G Tompkins

Abstract

The incidence of candidemia in patients with burns appears to be falling. However, when it occurs it remains a significant cause of morbidity and a potential cause of death. A 5-year retrospective review revealed that 138 (14.4%) of 962 pediatric patients who had been acutely burned had Candida species isolated from one or more sites during their hospital stay, but candidemia developed in only 17 patients (12.3% of those from whom Candida species were recovered and 1.8% of all admissions). Patients from whom Candida species were recovered at one site had a 0% incidence of candidemia, those from whom Candida species were recovered at two sites had a 22.2% incidence of candidemia, and those from whom Candida species were recovered at three or more sites had a 34.4% incidence of candidemia. These differences were significant by chi-square analysis (p < 0.0001). There was a low mortality rate associated with candidemia, with only one (5.9%) of the 17 patients dying as a direct result of invasive Candida infection. Nystatin administered enterally did not prevent the development of candidemia. Our review suggests that delay in biologic wound closure and exposure to broad-spectrum antibiotics are associated with an enhanced risk of ca...Continue Reading

Citations

Jan 25, 2003·Diagnostic Microbiology and Infectious Disease·Suzanne PulimoodPranatharthi Chandrasekar
Nov 10, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M Nucci, E Anaissie
Jan 17, 2003·Critical Care Medicine·Robert L Sheridan
Apr 29, 2005·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Robert L Sheridan
Oct 11, 2007·Journal of Burn Care & Research : Official Publication of the American Burn Association·David G GreenhalghUNKNOWN American Burn Association Consensus Conference on Burn Sepsis and Infection Group
Feb 11, 2011·The Journal of Trauma·Ana Filipa Bastos Pedrosa, Acácio Gonçalves Rodrigues
Dec 30, 2009·Journal of Perinatology : Official Journal of the California Perinatal Association·H B HarveyD S Morrell
Jun 15, 2013·Revista iberoamericana de micología·María E SantolayaUNKNOWN Grupo Proyecto Épico
Jun 15, 2013·Revista iberoamericana de micología·María E SantolayaUNKNOWN Latin America Invasive Mycosis Network
Mar 11, 2009·Burns : Journal of the International Society for Burn Injuries·C VinsonneauD Wassermann
Dec 11, 2007·American Journal of Infection Control·Jane D SiegelUNKNOWN Health Care Infection Control Practices Advisory Committee
Jun 6, 1998·Current Problems in Pediatrics·R L Sheridan
Sep 25, 2001·Current Problems in Surgery·R L Sheridan
Jul 11, 2016·Revista iberoamericana de micología·Ana Isabel RenauMiguel Salavert
Jan 10, 2008·Journal of Burn Care & Research : Official Publication of the American Burn Association·James BallardUNKNOWN Multicenter Trials Group, American Burn Association
Feb 26, 2010·Journal of Burn Care & Research : Official Publication of the American Burn Association·Edwina C MooreHeather Cleland
Jan 5, 2005·Mycopathologia·Nivedita GuptaRajendra Prasad
Nov 21, 2015·Jundishapur Journal of Microbiology·Nazanin LotfiNahid Kondori

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.